Thymosin Alpha 1
The thymic peptide that trains your immune system — approved as thymalfasin (Zadaxin) in 30+ countries for hepatitis and immune support. One of the most clinically validated peptides in existence.
Last updated: March 2026
📋 On this page
What Is Thymosin Alpha 1?
TA1 is a naturally occurring peptide in your thymus gland — the immune organ that matures T cells. It was originally isolated from bovine thymus tissue in the 1970s and later sequenced and synthesized as thymalfasin, marketed under the brand name Zadaxin. The synthetic form is bio-identical to the endogenous peptide.
How TA1 Works
Unlike most immune supplements that non-specifically stimulate, TA1 modulates — targeting the precise points of immune dysfunction without generating runaway inflammation.
TA1 promotes maturation and differentiation of T lymphocytes in the thymus. As the thymus involutes with age (especially after 40), T cell output drops — TA1 partially compensates for this thymic decline, improving circulating T cell numbers and function.
Dendritic cells are the immune system's scouts — they capture antigens and present them to T cells to initiate a targeted response. TA1 upregulates dendritic cell function and antigen presentation efficiency, improving the precision of adaptive immune responses.
NK cells are the immune system's rapid-deployment strike force — they destroy virus-infected and cancerous cells without prior sensitization. TA1 increases NK cell activity and cytotoxicity, particularly important for viral clearance and tumor surveillance.
Immune dysregulation often involves a shift toward TH2 dominance (allergic, anti-inflammatory) at the expense of TH1 (antiviral, anti-tumor). TA1 restores TH1/TH2 ratio, which is particularly relevant in chronic viral infections, post-COVID immune dysfunction, and certain autoimmune states.
One of TA1's most compelling longevity-relevant effects: it may help the immune system unmask senescent cells that have developed mechanisms to evade immune clearance. By upregulating immune surveillance, TA1 supports the body's natural senolytic (aging-cell clearing) processes.
Most immune compounds target one arm of immunity. TA1 is unusual in that it simultaneously modulates both innate immunity (fast, non-specific response) and adaptive immunity (learned, targeted response) — giving it broader utility than most immune-focused peptides.
What the Research Shows
TA1 has been studied in multiple disease contexts across decades — making it one of the better-documented peptides in clinical immunology.
Cross-trial caveat: The percentages above reflect clinical significance ratings based on the weight of evidence, not direct head-to-head comparison. Studies vary in design, populations, endpoints, and control conditions. Do not interpret these bars as directly comparable efficacy numbers.
TA1 + Epithalon Stack Protocol
A well-regarded pairing in the longevity and immune optimization community — TA1 for immune function, Epithalon for circadian regulation, telomerase activation, and pineal support.
| Peptide | Dose | Frequency | Timing | Route |
|---|---|---|---|---|
| Thymosin Alpha 1 | 1.5 mg | Twice weekly | Morning (AM) | SubQ injection |
| Epithalon | 5–10 mg | Daily (during cycle) | Evening (PM) | SubQ injection |
Acute viral illness: 2-week course, twice weekly TA1
Chronic immune support: 3+ months continuous dosing
Epithalon cycling: 2–3 week Epithalon burst at seasonal transitions (fall and spring) when immune demands shift
The morning/evening split is intentional. TA1 in the morning aligns with natural cortisol and immune activation cycles. Epithalon in the evening leverages its pineal gland mechanism — it promotes melatonin synthesis and circadian regulation, which would be disrupted by morning administration. Complementary without competing.
Weeks 1–2: Baseline immune labs (if tracking)
Weeks 2–3: Effects begin building — not immediately noticeable
Weeks 3–6: Most users report reduced illness frequency, faster recovery
Over 40: Most pronounced effects due to thymic decline
Effects are most noticeable in people over 40, where thymic involution has significantly reduced natural T cell output. Also particularly valuable for: post-viral immune dysfunction (Long COVID, chronic EBV), immunocompromised individuals, those with recurrent infections, and anyone seeking to optimize vaccine response.
Tracking Your Protocol
TA1 is one of the few peptides where you can objectively measure outcomes — immune parameters are well-established and testable.
- CBC with differential — T cell/NK cell ratios, lymphocyte count
- CMP — general metabolic baseline
- T cell subsets (CD4/CD8 ratio) if available from your provider
- Optional: NK cell cytotoxicity assay for detailed immune profiling
- Repeat CBC with differential — compare lymphocyte count and NK cell percentage
- Repeat T cell subsets if baseline was done — look for CD4/CD8 ratio normalization
- Document subjective: illness frequency, recovery speed, energy levels
Practical reality: Most users won't get T cell subset testing — it requires a provider who understands the ask and lab access. A basic CBC with differential is widely available and gives useful signal. Subjective tracking (infection frequency, recovery time, post-vaccine response) is often the most practical measure for most users.
What You Should Notice
Is TA1 Safe?
TA1 has one of the cleanest safety records of any peptide with clinical data — decades of use across tens of thousands of patients.
Landmark Studies
Key Takeaways
- 30+ countries have approved thymalfasin — extraordinary validation for a peptide
- Dual innate + adaptive immunity modulation is well-established mechanistically
- Robust hepatitis B and C clinical data showing improved viral clearance
- Excellent safety profile across decades of clinical use globally
- Strong rationale for 40+ population due to documented thymic decline
- COVID-19 pandemic added real-world data on T cell restoration applications
- Works synergistically with Epithalon in immune + longevity protocols
- Optimal dosing for healthy longevity/biohacking use — most data is from disease states
- Long-term effects of chronic TA1 use in healthy populations not established
- Long COVID data is still observational — no large RCTs in that specific context
- Unclear if periodic cycling is necessary or if continuous use is fine for healthy individuals
- Cancer immunotherapy results are mixed — not a standalone cancer treatment
- Senescent cell unmasking is mechanistically plausible but not directly proven in humans
🛒 Recommended Products
Supplies for peptide injection protocols
Affiliate links help support HighPeptides at no extra cost to you.
🔗 Related Resources
Explore the broader immune and longevity peptide landscape
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This content is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Thymosin Alpha 1 (thymalfasin) is not FDA-approved in the United States and is classified as a research peptide. It is approved in 30+ countries under various regulatory frameworks.
The clinical data presented refers to peer-reviewed published research. Extrapolating these findings to individual health decisions requires the guidance of a licensed medical professional familiar with peptide therapeutics. Do not start, stop, or modify any treatment protocol without consulting a qualified healthcare provider. HighPeptides does not sell peptides or medical treatments.